LSTM Home > LSTM Research > LSTM Online Archive

ST2 in patients with severe aortic stenosis and heart failure

Downloads

Downloads per month over past year

Cai, Andrew, Miyazawa, Alejandra, Sunderland, Nicholas, Piper, Susan E., Gibbs, Thomas G.J., Wang, Duolao ORCID: https://orcid.org/0000-0003-2788-2464, Redding, Sadie, Amin-Youseff, George, Wendler, Olaf, Byrne, Jonathan, MacCarthy, Philip A., Shah, Ajay M., McDonagh, Theresa A. and Dworakowski, Rafał (2019) 'ST2 in patients with severe aortic stenosis and heart failure'. Cardiology Journal. (In Press)

[img]
Preview
Text
62738-183536-1-PB.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

Background:
ST2 is a circulating biomarker that is well established for predicting outcome in heart failure (HF). This is the first study to look at ST2 concentrations in optimally treated patients with stable but significant left ventricular systolic dysfunction (LVSD) compared to patients with severe aortic stenosis (AS).

Methods:
Two cohorts were retrospectively studied: 94 patients undergoing transcatheter aortic valve implantation for severe AS (63 with normal ejection fraction [EF] and 31 with reduced EF), and 50 patients with severe LVSD from non-valvular causes. ST2 pre-procedural samples were taken, and repeated again at 3 and 6 months. Patients were followed-up for 2 years. Data was analyzed using SPSS software.

Results:
Baseline concentrations of soluble ST2 did not differ significantly between the HF group and AS group with normal EF (EF ≥ 50%). However, in the AS group with a low EF (EF < 50%) ST2 concentrations were significantly higher that the HF group (p = 0.009). New York Heart Association class IV HF, baseline N-terminal pro-B-type natriuretic peptide and gender were all independent predictors of soluble ST2 (sST2) baseline concentrations.

Conclusions:
Raised ST2 concentrations in the context of severe AS may be a marker for subclinical or clinical left ventricular dysfunction. More research is required to assess its use for assessment of prognosis and response to treatment.

Item Type: Article
Subjects: QW Microbiology and Immunology > Immunity by Type > QW 541 Natural immunity. Immunogenetics
WG Cardiovascular System > WG 100 General works
WG Cardiovascular System > Heart. Heart Diseases > WG 200 General works
Faculty: Department: Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI): https://doi.org/10.5603/CJ.a2019.0052
Depositing User: Marie Hatton
Date Deposited: 02 Aug 2019 14:10
Last Modified: 29 Oct 2020 10:06
URI: https://archive.lstmed.ac.uk/id/eprint/11343

Statistics

View details

Actions (login required)

Edit Item Edit Item